CTL-killing capacity and cancer stiffness in cancer immunity and therapy

癌症免疫和治疗中的 CTL 杀伤能力和癌症硬度

基本信息

批准号：
10548120
负责人：
WEIPING ZOU
金额：
$ 63.44万
依托单位：
UNIVERSITY OF MICHIGAN AT ANN ARBOR
依托单位国家：
美国
项目类别：
财政年份：
2022
资助国家：
美国
起止时间：
2022-01-07 至 2026-12-31
项目状态：
未结题

来源：
https://reporter.nih.gov/project-details/10548120
关键词：
Aerobic Affect Air Movements Amino Acid Transporter Amino Acids Attention Biological Biomechanics Breast Cancer Cell CD8-Positive T-Lymphocytes Cell Proliferation Cell membrane Cells Characteristics Chemoresistance Cytoplasmic Granules DNA Sequence Alteration Data Development Effector Cell Elasticity Epigenetic Process Event FOXP3 gene Genetic Glutamine Goals Granzyme Human Hypoxia Immune Immune Evasion Immune response Immune system Immunity Immunologic Sensitization Immunologics Immunology Immunotherapeutic agent Immunotherapy Impairment Interferons Link Lytic Malignant Neoplasms Measurement Mechanics Mediating Mediator Membrane Metabolic Metabolism Microscope Molecular Mus Mutation Myeloid-derived suppressor cells Myosin Type II Nature Neoplasm Metastasis Oncology Pathology Pathway interactions Patient-Focused Outcomes Patients Phenotype Predisposition Process Regulation Regulatory T-Lymphocyte Research Resistance Role Scanning Probe Microscopes Signal Pathway Solid Neoplasm Spectrometry, Mass, Electrospray Ionization T-Lymphocyte Techniques Testing Tissues Tumor Immunity Warburg Effect aerobic glycolysis amino acid metabolism cancer cell cancer genetics cancer stem cell cancer therapy cell killing cytotoxic cytotoxic CD8 T cells effector T cell empowerment imaging system immune checkpoint blockade immune resistance interdisciplinary approach laser tweezer mass spectrometric imaging migration neoplasm immunotherapy neoplastic cell novel optic tweezer perforin resistance mechanism stem-like cell stemness tool trafficking tumor tumor initiation tumor metabolism tumor microenvironment uptake

项目摘要

Project Summary/Abstract: CD8+ T cells (CTLs) mediate protective tumor immunity. The goal of tumor immune therapy is to engender long-term protective effector T cell immunity and cause tumor eradiation in patients with cancer. To this end, tumor cells must be receptive and susceptible to CTL-mediated tumor killing. However, in addition to the quality and quantity of CTLs, what determines tumor cell receptivity to CTL- mediated tumor killing is poorly understood. It is essential to conduct comprehensive molecular and functional research on the nature of tumor cell receptivity to CTLs in the human tumor microenvironment. Tumor biologists have been working on how tumor metabolism enables tumor cell proliferation, survival, and invasiveness without a comprehensive consideration of the immune involvement. Recent immunological studies have started to examine how tumor metabolism affects the phenotype and function of different immune cell subsets in the tumor microenvironment. Yet, how tumor metabolism affects tumor cell receptivity to CTL- killing is basically unknown. Having established an Optical Tweezers Microscope (OTM) technique and Atomic Force Microscope (AFM) for cell elasticity and stiffness measurements and applied an airflow-assisted desorption electrospray ionization mass spectrometry imaging (AFADESI-MSI), we are able to preliminarily demonstrate that human and mouse breast tumor cells empowered with particular amino acid uptake resulted in reduced myosin II-mediated contractile activation and tumor cell stiffness. Loss of tumor stiffness led to tumor cell membrane resistance to perforin drilling force and pore formation by CTLs, resulting in impaired T cell-mediated tumor killing. Mechanistically, tumor cells were addicted to certain amino acids, including glutamine, via high expression of SLC6A14, a glutamine transporter. Interestingly, tumor SLC6A14 expression was controlled by hypoxia. These data reveal previously unknown mechanisms of connection between specific amino acid metabolism, hypoxia, and T cell immunity in the tumor microenvironment, thereby identifying cancer glutamine transporter(s) as a potential novel immune metabolic checkpoint target. Based on these surprising and novel findings, we hypothesize that cancer cell stiffness determines tumor cell receptivity to CTL-killing, and the interplay between hypoxia and particular amino acid uptake is a novel immune evasion mechanism in the tumor microenvironment. We propose two specific aims and 8 subaims to test our central hypothesis that hypoxia targets tumor amino acid transporters, exemplified by SLC6A14, to alter tumor cell receptivity to CTL-killing and tumor immunity and therapy. Our specific aims are: Aim 1 is to test our hypothesis that hypoxia metabolically weakens tumor receptivity to CTL-killing. Aim 2 is to test our hypothesis that hypoxia mechanically weakens tumor receptivity to CTL-killing.

项目摘要/摘要：CD8+ T 细胞 (CTL) 介导保护性肿瘤免疫。肿瘤的目标免疫疗法的目的是产生长期的保护性效应T细胞免疫并导致肿瘤根除癌症患者。为此，肿瘤细胞必须能够接受并易受 CTL 介导的肿瘤杀伤作用。然而，除了 CTL 的质量和数量外，决定肿瘤细胞对 CTL 接受性的因素还有哪些？介导的肿瘤杀伤作用尚不清楚。有必要进行全面的分子和功能研究研究人类肿瘤微环境中肿瘤细胞对 CTL 的感受性性质。肿瘤生物学家一直致力于研究肿瘤代谢如何促进肿瘤细胞增殖、存活和生存。没有全面考虑免疫参与的侵袭性。近期免疫学研究已经开始研究肿瘤代谢如何影响不同免疫的表型和功能肿瘤微环境中的细胞亚群。然而，肿瘤代谢如何影响肿瘤细胞对 CTL-的接受性杀戮基本上是未知的。建立了光镊显微镜（OTM）技术和原子力显微镜 (AFM) 用于细胞弹性和刚度测量，并应用气流辅助通过解吸电喷雾电离质谱成像（AFADESI-MSI），我们能够初步证明人类和小鼠乳腺肿瘤细胞具有特定氨基酸摄取能力减少肌球蛋白 II 介导的收缩激活和肿瘤细胞硬度。肿瘤硬度的丧失导致肿瘤细胞膜对穿孔素钻孔力和 CTL 形成孔的抵抗力，导致 T 细胞受损细胞介导的肿瘤杀伤。从机制上讲，肿瘤细胞对某些氨基酸上瘾，包括谷氨酰胺，通过谷氨酰胺转运蛋白 SLC6A14 的高表达。有趣的是，肿瘤SLC6A14表达是通过缺氧来控制的。这些数据揭示了以前未知的特定之间的联系机制肿瘤微环境中的氨基酸代谢、缺氧和 T 细胞免疫，从而识别癌症谷氨酰胺转运蛋白作为潜在的新型免疫代谢检查点靶标。基于这些令人惊讶和新颖的发现，我们假设癌细胞硬度决定肿瘤细胞对 CTL 杀伤的感受性，以及缺氧和特定氨基酸摄取之间的相互作用是一种新的机制。肿瘤微环境中的免疫逃避机制。我们提出了两个具体目标和 8 个子目标检验我们的中心假设，即缺氧针对肿瘤氨基酸转运蛋白（以 SLC6A14 为例），以改变肿瘤细胞对 CTL 杀伤以及肿瘤免疫和治疗的接受性。我们的具体目标是：目标 1 是检验我们的假设，即缺氧代谢会削弱肿瘤对 CTL 杀伤的感受性。目标 2 是检验我们的假设，即缺氧会机械地削弱肿瘤对 CTL 杀伤的感受性。